084990:KOSDAQ
Helixmith Co Ltd
₩4,090.00
arrow_downward
-3.88%(-165.00) 1D
Jun 25, 12:49:15 PM GMT+9 · KRW
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 084990...
Open
₩4,255
High
₩4,385
Low
₩4,065
Mkt. cap
188.52B
Avg. vol.
474.49K
Volume
106.93K
52-wk high
₩9,960
52-wk low
₩2,795
EPS
-₩7
Shares outstanding
46.09M
No. of employees
38
Open
₩4,255
High
₩4,385
Low
₩4,065
Mkt. cap
188.52B
Avg. vol.
474.49K
Volume
106.93K
52-wk high
₩9,960
52-wk low
₩2,795
EPS
-₩7
Shares outstanding
46.09M
No. of employees
38
News stories
From sources across the web
Texarkana Gazette
·
1 hour ago
U.S. stocks end mixed, weighed down by more losses for tech giants
EBC Financial Group
·
1 hour ago
Alphabet to Replace Verizon in Dow Jones, But AI Doubts Weigh on GOOGL Stock
Profile
Helixmith Co. LTD. is a biotechnology company located in Seoul, South Korea with US presence in San Diego. The company has an extensive gene therapy pipeline, including a non-viral plasmid DNA program for neuromuscular and ischemic disease, a CAR-T program targeting several different types of solid tumors, and an AAV vector program targeting neuromuscular diseases. Helixmith’s lead gene is Engensis, currently in phase III diabetic peripheral neuropathy in the US. Engensis is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor, HGF 728 and HGF 723. In addition to DPN, Engensis is also being studied in diabetic foot ulcers, amyotrophic lateral sclerosis, coronary artery disease, claudication, and Charcot-Marie-Tooth disease. Wikipedia
About Helixmith Co Ltd
AI content may include mistakes. Learn more